ONWARD Medical has raised €40.6 million in a private placement priced at €3.00 per share, the Eindhoven-headquartered neurotechnology company announced on 16 April. The accelerated bookbuild was led by EQT Life Sciences, which committed €25 million and was joined by what the company described as long-only and sector-specialist institutional investors. ONWARD issued 13,520,254 new ordinary shares, with trading in the new stock on Euronext Amsterdam, Brussels, and Paris expected to begin on 20 April under the ticker ONWD. The company also trades as an American depositary receipt under ONWRY.
ONWARD said net proceeds, combined with existing cash and an undrawn debt facility, extend its runway into the first quarter of 2028. The raise closes a 12-month cycle in which the company has moved from a primarily research-stage profile to a commercialization-stage one, and the allocation of the fresh capital reflects that change.
Where the money goes
ONWARD disclosed a four-way split on use of proceeds. Forty per cent is earmarked for ARC-IM, its investigational implantable spinal cord stimulation system, including clinical studies and regulatory work. Thirty per cent goes to expanding sales and commercial operations for the ARC-EX System across the United States, Europe, and selected international markets. Twenty per cent is allocated to quality and administrative functions, and the remaining ten per cent to working capital, general corporate purposes, and servicing existing debt.
The 30 per cent commercial allocation is the signal to watch. ARC-EX, a non-invasive stimulator designed to improve upper-limb function after spinal cord injury, received FDA De Novo authorization in the United States in December 2024, followed by FDA 510(k) clearance for home use in November 2025, alongside commercial availability in Europe. The commercial allocation is for distribution: field force, account penetration, and payer engagement in a category where reimbursement mechanics will determine the revenue curve.
The ARC-IM option
The longer-dated bet is ARC-IM, an implantable spinal cord stimulation system. ONWARD’s initial regulatory target is blood pressure instability after spinal cord injury, a condition affecting a large share of chronic SCI patients with no effective drug treatment. The company is running a pivotal trial called Empower BP to support that indication. ONWARD has also described ARC-IM as compatible with brain-computer interface input and artificial intelligence for thought-driven movement, and a combined ARC-IM plus BCI system has already been implanted in humans to restore arm, hand, and finger function.
That positioning places the platform adjacent to the Neuralink- and Synchron-led read-side of the BCI market. ARC-IM itself sits on the stimulation side of the field, where the engineering problem is restoring motor output to the body. Read-side BCI companies generate revenue through signal acquisition and decoding, a market that remains pre-approval for most commercial indications outside research consent. Stimulation technology, by comparison, has a decades-long regulatory pathway already established through spinal cord stimulators for chronic pain, a multi-billion-dollar category dominated by Nevro, Boston Scientific, and Medtronic. ARC-IM, if approved, would enter that adjacent reimbursement landscape with a new indication in an existing device category.
ONWARD holds 10 FDA Breakthrough Device Designations across its pipeline, among the highest counts in neurotechnology. The most recent, awarded in February 2024, was for the ARC-BCI System itself. Breakthrough Device Designation does not guarantee approval but can compress review timelines and signals FDA agreement that the underlying indications meet the threshold of “more effective treatment” for a serious condition.
Investor signal
EQT Life Sciences’ €25 million commitment is the most readable line in the announcement. The Amsterdam-based healthcare specialist has been an ONWARD investor since 2016, through its predecessor LSP, and a lead position of that size at a €3.00 issue price indicates continuing institutional support for the cash burn required to move ARC-IM to its next clinical milestones. Additional long-only institutional participation, even unnamed, indicates that public-market appetite at this stage remains aligned with the company’s milestone narrative.
The raise also follows an October 2025 €50.85 million private placement anchored by German prosthetics group Ottobock, taking disclosed capital intake over the past 12 months to roughly €91 million. The current round provides around seven quarters of runway at current burn, assuming no draw on the debt facility. That is enough capital to move ARC-IM through a meaningful clinical readout or an initial regulatory submission. Subsequent financing will depend on trial outcomes.
Context for the sector
ONWARD’s raise lands in a market where BCI and adjacent neurotechnology capital has concentrated around a small number of named companies. Neuralink, Synchron, Precision Neuroscience, and Paradromics dominate the private-funding conversation on the read side, which focuses on decoding neural signals. On the stimulation side, where the goal is to restore motor function through the spinal cord, ONWARD is the only European-listed pure-play and one of a handful globally with a clinical-stage implantable programme.
The company was co-founded by Grégoire Courtine of EPFL, who remains a scientific advisor. Its academic partner .NeuroRestore, a joint EPFL and CHUV centre in Lausanne, produced the foundational human walking-restoration work underpinning the ARC platform. CEO Dave Marver, a 15-year Medtronic veteran, joined in 2020 and took the company public on Euronext in October 2021.
The structural question worth watching is whether read-side BCI companies will eventually need to acquire or partner with stimulation platforms to deliver end-to-end function restoration. If that convergence plays out, ARC-IM becomes strategically relevant beyond its standalone indications. The 16 April raise gives ONWARD the runway to reach that point.